-1752954591090.webp&w=3840&q=75)
2025 NOSCM | Immunotherapy in Head and Neck Cancers
Overview
Dr. Robert Haddad shared advances in head and neck cancer, highlighting perioperative pembrolizumab's FDA approval. Unlike past trials, Keynote 689 showed improved event-free survival. Nivo Post-Op also benefited high-risk patients, underscoring multidisciplinary care's role in treatment progress.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Robert Haddad, MD
Date of Release
July 20th, 2025
Related Material
-1769183671548.webp&w=3840&q=75)
2026 MCM | Dealing with Long Term Effects of Breast Cancer Immunotherapy and Targeted Therapy
Immunotherapy
1 Chapter
Non-CME Credit Course
-1769183559393.webp&w=3840&q=75)
2026 MCM | Integrative Medicine and Cancer: How to Improve the Quality of Life and Well Being of Our Patients and Survivors
Immunotherapy
1 Chapter
Non-CME Credit Course